Global obesity is on the rise, and endocrinologists are at the forefront of diagnosing its underlying causes and prescribing treatment plans. The Society works to reduce prevalence of obesity through various means, including development and release of scientific statements and practice guidelines, and advocacy for policies and positions that ensure access to affordable treatments. As new obesity medications come to market, the Society will play an important role in educating providers and patients on their optimal usage.
Daniel Drucker, MD, recent winner of our Lifetime Achievement Laureate Award, the top honors in the field, shares his story as one of the first researchers to discover GLP-1s for treating diabetes and obesity in a new video series on obesity care. Watch part 4 of our "Talking Obesity with Experts" video series and browse related resources on our Focus on Obesity page. Check out this video and other obesity-related videos.
Video 4: Talking Obesity with Daniel Drucker: How Has the Endocrine Society Helped Advance Your Career?
Obesity is a complex disease that is associated with various comorbidities, increased mortality, and reduced quality of life. Abdominal obesity is one of the components of metabolic syndrome (MetS), a cluster of risk factors that increases an individual’s risk for chronic conditions such as cardiovascular disease and diabetes. View our new Facts and Figures infographic and Obesity Playbook. Learn more about the science of obesity in our 2023 Thematic Issue on Obesity.
Read our “Obesity Playbook," updated March 2024. This educational resource on obesity and health is designed for Congressional staff, covering the latest facts and figures, the state of science, and policy options.
